BioPharma Credit (LSE: BPCR) is one of the more esoteric investment trusts listed in London. Biotech is a specialist sector that I usually wouldn’t touch with a barge pole. The risk of failure is very high, and even the experts are often wrong-footed by a surprising trial result, court case or even fatality. However, as is often the case, uncertainty and complexity create opportunities.
BioPharma lends money to small- and mid-sized life sciences companies. Most of the borrowers are public companies, and the trust is lending against their future cash flows, with the loans secured by asset values.
“For the most part, our borrowers are asset rich,” says Pedro Gonzalez de Cosio, co-founder and chief executive officer of Pharmakon Advisors, the specialist biotechnology investor that manages the trust. “They are a monopoly in treating a certain disease in a certain way. [They] have very high gross margins [and] very valuable assets, but most of these companies are at a stage where they are probably still investing more in launching the product… So they have these assets worth a lot of money, but they’re still burning cash.”
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
BioPharma isn’t the only player in its sector, but this type of specialist life-sciences lending requires experience and a strong pipeline cultivated by reputation and knowledge to succeed. Pharmakon has been around since 2009 and has invested nearly $10 billion so far through the trust and other private funds (BioPharma usually partners with another Pharmakon fund on its deals). “We’ve only had to put a company into default once,” says Gonzalez de Cosio, and even on this default, the fund has recovered more than 90% of its investment.
BioPharma’s portfolio is relatively concentrated. At the end of January, just over 60% of the portfolio was allocated to just three senior loans to three separate companies. However, the portfolio shouldn’t be viewed in isolation, says Gonzalez de Cosio. “I can guarantee you that [by] investing in us [you] diversify your portfolio because there is no other way that you can get access to these assets.”
BioPharma's early repayments
When BioPharma listed in 2017, it committed to an annual dividend of 7% or $0.07 on the $1 per share issue price. It has topped this return up over the past three years with additional special dividends. Over the past three years, the trust has paid out $0.33 per share, or an average of $0.11 per year. It’s been able to do this as the bulk (78%) of the portfolio is floating rate and because companies generally commit to additional payments if the bonds are repaid earlier than scheduled.
For example, in November 2022, Immunocore took out a $50 million senior secured loan, funded jointly by the trust and BioPharma Credit Investments V. The floating rate note was set for repayment in November 2028 and paid an interest rate of 9.75%. In November last year, it was repaid early. Immunocore had to pay a $1.5 million early repayment fee, of which the investment trust received $750,000, as well as accrued interest of $264,000.
In May 2023, BioPharma loaned $25 million to Reata Pharmaceuticals, which owned the rights to the first and only approved treatment for Friedreich’s ataxia (FA) – a rare inherited and progressive neurodegenerative disorder – in the United States. Three months later, Reata was acquired for $7.3 billion by Biogen. Reata had committed to pay two years of interest on the loan, so when the acquisition took place, it had to pay interest upfront as well as the principal and early repayment fees. BioPharma booked a 141% internal rate of return.
BioPharma offers something different from a unique asset class. Currently, it is trading at a double-digit discount to its January net asset value (NAV) of $0.975. It paid $0.10 in regular and special dividends last year and in 2023, and while the special payouts are not guaranteed, that amounts to a trailing dividend yield of 11%.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Five years on: what did Covid cost us?We’re still counting the costs of the global coronavirus pandemic – and governments’ responses. What did we learn?
-
New tax year changes: how much will you have to pay in 2025/26?The new tax year will start on 6 April, 2025. We look at how taxes and allowances are changing and how they will affect you.
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
-
Pensions revolution: how to profit from the trends shaping the UK pension systemThe UK pension system is one of the biggest in the world. Big changes are under way, says Rupert Hargreaves
-
Large cap stocks start to struggle – is it time for investors to reassess their focus?Buying quality large caps worked very well last decade. A more volatile world will be a bigger challenge for these star stocks, says Cris Sholto Heaton
-
How to generate income with fixed-interest investmentsPublic debt is overvalued, but other fixed-interest investments now look like a bargain, says Max King
-
Three top-notch Taiwanese companies cashing in on the advent of AIOpinion Eric Chan, investment director and co-manager of the Aberdeen Asian Income Fund, highlights three potential Taiwanese winners in the technology industry
-
Boaz Weinstein: the hedge fund ‘vulture’ swooping on the CityProfile Boaz Weinstein’s campaign to take over and transform “the Miserable Seven” London-based investment trusts has been routed – for now. The fight isn’t over yet
-
Weight-loss drugs could revolutionise the economy – the investments to buy nowThe new generation of weight-loss drugs are a boon for the overweight, but they also promise to change our relationship with food and revolutionise the economy
-
Find tomorrow’s Asian giants while they are still smaller companiesOpinion Nitin Bajaj, portfolio manager of the Fidelity Asian Values trust, picks three Asian companies to invest in.
